WO2024076993A3 - Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use - Google Patents
Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use Download PDFInfo
- Publication number
- WO2024076993A3 WO2024076993A3 PCT/US2023/075840 US2023075840W WO2024076993A3 WO 2024076993 A3 WO2024076993 A3 WO 2024076993A3 US 2023075840 W US2023075840 W US 2023075840W WO 2024076993 A3 WO2024076993 A3 WO 2024076993A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fibrinogen
- domain
- growth factor
- antigen binding
- binding proteins
- Prior art date
Links
- 102000008946 Fibrinogen Human genes 0.000 title abstract 3
- 108010049003 Fibrinogen Proteins 0.000 title abstract 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title abstract 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 3
- 102000025171 antigen binding proteins Human genes 0.000 title abstract 3
- 108091000831 antigen binding proteins Proteins 0.000 title abstract 3
- 229940012952 fibrinogen Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229940106780 human fibrinogen Drugs 0.000 title abstract 2
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Described herein are multi-specific antigen binding proteins that bind human fibrin or fibrinogen γC domain and vascular endothelial growth factor, and methods of use thereof. In certain aspects, described herein are pharmaceutical compositions comprising the multi- specific antigen binding proteins that bind fibrin or fibrinogen γC domain and vascular endothelial growth factor. In certain aspects, the antibodies and methods described herein are used for treatment of disorders or conditions of the eye.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263412833P | 2022-10-03 | 2022-10-03 | |
| US63/412,833 | 2022-10-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2024076993A2 WO2024076993A2 (en) | 2024-04-11 |
| WO2024076993A3 true WO2024076993A3 (en) | 2024-05-16 |
Family
ID=90609012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2023/075840 WO2024076993A2 (en) | 2022-10-03 | 2023-10-03 | Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024076993A2 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5632968A (en) * | 1991-05-06 | 1997-05-27 | Immunomedics, Inc. | Detection of cardiovascular lesions |
| US20150004166A1 (en) * | 2008-10-08 | 2015-01-01 | Hoffmann-La Roche Inc. | Bispecific anti-vegf/anti-ang-2 antibodies |
| US20180355061A1 (en) * | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that Specifically Bind PD-1 and Methods of Use |
| WO2022159776A1 (en) * | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Antibodies which bind human fibrin and methods of use |
-
2023
- 2023-10-03 WO PCT/US2023/075840 patent/WO2024076993A2/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5632968A (en) * | 1991-05-06 | 1997-05-27 | Immunomedics, Inc. | Detection of cardiovascular lesions |
| US20150004166A1 (en) * | 2008-10-08 | 2015-01-01 | Hoffmann-La Roche Inc. | Bispecific anti-vegf/anti-ang-2 antibodies |
| US20180355061A1 (en) * | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that Specifically Bind PD-1 and Methods of Use |
| WO2022159776A1 (en) * | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Antibodies which bind human fibrin and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024076993A2 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davis et al. | Platelet-rich preparations to improve healing. Part II: platelet activation and enrichment, leukocyte inclusion, and other selection criteria | |
| PH12021550793A1 (en) | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | |
| EP4364724A3 (en) | High concentration vegf receptor fusion protein containing formulations | |
| DE602004031390D1 (en) | Coagulation factor VII-Fc chimeric proteins for the treatment of hemostatic diseases | |
| EP4272838A3 (en) | Designed ankyrin repeat domains with binding specificity for serum albumin | |
| AU2018271872A1 (en) | A protein binding NKG2D, CD16 and ROR1 or ROR2 | |
| WO2010065077A3 (en) | Antagonists of il-6 to prevent or treat thrombosis | |
| AU2002305450A1 (en) | Proteomimetic compounds and methods | |
| EA201992570A1 (en) | COMPOSITIONS BASED ON HUMAN ANTIBODIES TO RANKL, AND ALSO WAYS OF THEIR APPLICATION | |
| AU2017267370A1 (en) | A method to enhance wound healing using silk-derived protein | |
| WO2022167816A3 (en) | Antibodies | |
| CR20220646A (en) | Sars-cov-2 antibodies and methods of selecting and using the same | |
| WO2019014360A8 (en) | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof | |
| CR20220329A (en) | Anti-mertk antibodies and methods of use thereof | |
| BR112021018632A2 (en) | CD3-binding molecules | |
| BR112023002455A2 (en) | FGFR3 ANTIBODIES AND METHODS OF USE | |
| MX2022001626A (en) | Biopharmacuetical compositions and related methods. | |
| DE60215649D1 (en) | COMPOSITIONS AND METHODS FOR TREATING HYPERIMMUNE REACTIONS IN THE EYE | |
| EA202092593A1 (en) | PROTEINS BINDING THE CANNABINOID RECEPTOR TYPE 1 (CB1) AND THEIR APPLICATION | |
| WO2024076993A3 (en) | Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use | |
| DE60319135D1 (en) | PEPTIDES BINDING THE HEPARIN BINDING DOMAIN OF VEGF AND VEGFR-2 | |
| MX2023009360A (en) | Anti-tcr delta variable 1 antibodies. | |
| MX2023009681A (en) | Anti-tl1a antibody compositions and methods of treatment in the lung. | |
| BR112022021750A2 (en) | ANTI-APC MONOCLONAL ANTIBODY, BIOLOGICAL MATERIAL RELATED TO ANTI-APC MONOCLONAL ANTIBODY, PRODUCT FOR THE PREPARATION AND USE OF ANTI-APC MONOCLONAL ANTIBODY OR BIOLOGICAL MATERIAL | |
| WO2021058711A3 (en) | Antigen binding proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23875704 Country of ref document: EP Kind code of ref document: A2 |